Clinical trial NCT01824251: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Official title: NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Keywords: IVIG in Chronic Inflammatory Demyelinating Polyneuropathy
Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Lead sponsor: Nihon Pharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2013-04-04
Enrollment: 49
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy were confirmed based on the European Federation of Neurological Societies/ Peripheral. Nerve Society Guideline. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Subsequently, patients receive NPB-01 1g/kg every 3weeks and evaluate the Inflammatory Neuropathy Cause and Treatment（INCAT） score and INCAT sensory sumscore（ISS） et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by one year after the start of the study treatment.


Eligibility criteria: Inclusion Criteria:

* 1. Patients with progressive or relapsing motor and sensory dysfunction of more than one limb resulting from neuropathy within 2 months prior to the date informed consent is obtained.
* 2. Patients who INCAT score between 2-9. (If the INCAT score is 1 in upper limb, the INCAT score of 2 must be exclusively from leg disability to qualify.)
* 3. Patients who need high-dose intravenous immunoglobulin therapy.
* 4. Patients who continued treatment for CIDP without addition or increase at 30 days before informed consent.
* 5. Patients with greater than or equal to twenty years old at informed consent.

Exclusion Criteria:

* 1. Patients with evidence of myelopathy or demyelination of central nerve
* 2. Patients with evidence of stroke, central nerve system trauma, or persistent neurological deficits due to peripheral neuropathy from other causes（diabetic neuropathy, IgM paraproteinaemia, uraemic neuropathy, toxic neuropathy, hereditary neuropathy）
* 3. Patients with evidence of neuropathy or alcoholic neuropathy or vitamin deficiency neuropathy due to myeloma, lymphoma, sarcoidosis, systemic lupus erythematosus, malignancy, vasculitis, Crow-Fukase syndrome, Sjögren syndrome.
* 4. Patients with multifocal motor neuropathy.
* 5. Patients treated with plasmapheresis at 3 months before informed consent.
* 6. Patients treated with rituximab at 6 months before informed consent.
* 7. Patients treated with high-dose intravenous immunoglobulin（greater than or equal to 1g/kg） at 8 weeks before informed consent.
* 8. Patients treated with intravenous immunoglobulin at 3 weeks before informed consent.
* 9. Patients with history of shock or hypersensitivity for NPB-01.
* 10. Patients with IgA deficiency.
* 11. Patients with malignancy at informed consent.
* 12. Patients with impaired liver function.
* 13. Patients with impaired renal function.
* 14. Patients with cerebro- or cardiovascular disorders.
* 15. Patients with high risk of thromboembolism.
* 16. Patients with hemolytic/hemorrhagic anemia.
* 17. Patients with decreased cardiac function.
* 18. Patients with decreased platelet.

Primary outcomes:
measure: proportion of patients with more than 1point improvement in the INCAT score relative to baseline at 28weeks.
timeFrame: 28weeks
measure: proportion of patients with more than 1point exacerbation in the INCAT score relative to 28weeks at 52weeks.
timeFrame: 52weeks
Secondary outcomes:
measure: INCAT score
timeFrame: 1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks
measure: ISS
timeFrame: 1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks
measure: maximum grip strength
timeFrame: 1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks
measure: Medical Research Council（MRC） sum score
timeFrame: 1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52weeks
measure: the amplitude of the compound muscle action potential of the most severely affected motor nerve
timeFrame: 1,4,28,52weeks
Other outcomes:
Locations:
city: Osaka
country: Japan
facility: Nihon Pharmaceutical Co., Ltd
Study officials:
References:
citation: Kuwabara S, Mori M, Misawa S, Suzuki M, Nishiyama K, Mutoh T, Doi S, Kokubun N, Kamijo M, Yoshikawa H, Abe K, Nishida Y, Okada K, Sekiguchi K, Sakamoto K, Kusunoki S, Sobue G, Kaji R; Glovenin-I CIDP Study Group. Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):832-838. doi: 10.1136/jnnp-2017-316427. Epub 2017 Aug 2.